Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (728)	2/22/1998 8:18:00 PM
From: Vector1	Read Replies (3) \| Respond to of 1826

<<Could you point us to some actual examples? Were the failures because of toxicity or lack of efficacy or both>> The examples are too numerous to list. Among the primary reasons are toxicity and the fact that Xenografted human tumors are not metastatic. There was an excellent article on this issue in the november 7th issue of Science entitled Cancer Models: Systems for identifying new drugs are often faulty. You can get a copy or at least an abstract by registering with Science on line www.sciencemag.org. V1

To: Biomaven who wrote (728)	2/26/1998 7:20:00 PM
From: seminole	Respond to of 1826

Peter Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114) Thanks for posting the reference. I have read the article. The article contain an incredible amount of experimental work. The work was completed by the Cancer Therapy and Research Center and MGI Pharma both of whom are directly involved with the Phase I clinical trials. Of interest to myself only (probably), the work was undertaken and published as MGI Pharma determines which cell line they want to select for Phase II clinical trials. So why was all this work done on the CEM, human leukemia, cell line? Why not select a cell line used before (MX-1 breast carcinoma, MCF7 breast adenocarcinoma , MV522 lung, HT-29 colon, etc.)? Why not select the cell type you expect to study in Phase II clinical trials? richard